Safety of tiotropium Respimat® add-on therapy in patients aged 6-17 years with symptomatic asthma Source: International Congress 2016 – Drugs, bugs, BMI, and other problems in paediatric asthma Year: 2016
Once-daily tiotropium Respimat® add-on therapy improves PEF in participants aged 6-17 years with symptomatic asthma Source: International Congress 2016 – Drugs, bugs, BMI, and other problems in paediatric asthma Year: 2016
Efficacy of montelukast in patients aged 2 to 5 years with mild asthma Source: Eur Respir J 2004; 24: Suppl. 48, 377s Year: 2004
Montelukast vs. fluticasone in patients aged 6 to 14 with mild persistent asthma: the MOSAIC study Source: Eur Respir J 2004; 24: Suppl. 48, 377s Year: 2004
Asthma control and quality of life in asthmatic patients treated for 6 months with FDC Budesonide/Formoterol - BOREAS study: a subgroup analysis in patients with comorbidities Source: International Congress 2019 – Asthma treatment: cohorts and real-world studies Year: 2019
Follow-up results 10 years after early intervention with budesonide or terbutaline in mild persistent asthma Source: Eur Respir J 2006; 28: Suppl. 50, 667s Year: 2006
Safety of formoterol in children and adolescents: experience from asthma clinical trials Source: Annual Congress 2008 - Drug therapy and assessment of control in childhood asthma Year: 2008
Cost variations of asthma over 10 years in adults Source: International Congress 2018 – Asthma and allergy in adults and children and their biomarkers Year: 2018
Formoterol in acute asthma in children 6-14 years old Source: Eur Respir J 2003; 22: Suppl. 45, 133s Year: 2003
The TORCH (TOwards a Revolution in COPD Health) study: salmeterol/ fluticasone propionate (SFC) is well tolerated in patients with COPD over three years Source: Eur Respir J 2006; 28: Suppl. 50, 34s Year: 2006
Cost-effectiveness of early intervention with once-daily budesonide in children with mild persistent asthma: results from the START study Source: Eur Respir J 2003; 22: Suppl. 45, 34s Year: 2003
Health care resource utilization following addition of montelukast or salmeterol to fluticasone in patients with inadequately controlled asthma (IMPACT trial) Source: Eur Respir J 2004; 24: Suppl. 48, 127s Year: 2004
Effect of 5 years of budesonide treatment on growth and adult height in asthmatic children: results from the START study Source: Eur Respir J 2004; 24: Suppl. 48, 211s Year: 2004
The TORCH (TOwards a Revolution in COPD Health) study: salmeterol/fluticasone propionate (SFC) improves survival in COPD over three years Source: Eur Respir J 2006; 28: Suppl. 50, 34s Year: 2006
Efficacy and safety of once-daily (OD) fluticasone furoate (FF) 50mcg over 24 weeks in adults and adolescents with persistent asthma Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs Year: 2013
Efficacy and safety of once-daily (OD) fluticasone furoate (FF) in adults and adolescents with moderate-to-severe persistent asthma Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs Year: 2013
Clinical predictors of the effectiveness of tiotropium in adults with symptomatic asthma: the real-life data Source: International Congress 2018 – Tests and trends in asthma Year: 2018
Efficacy and safety of QVA149 compared with salmeterol/fluticasone combination (SFC) in Chinese patients with moderate-to-severe COPD: A subgroup analysis from the LANTERN study Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD Year: 2015
Improvement in HRQoL of COPD patients after 9 months‘ treatment with tiotropium bromide: use of a new scale for daily medical practice Source: Eur Respir J 2005; 26: Suppl. 49, 290s Year: 2005
Safety and effectiveness of indacaterol in Korean COPD patients: A post-marketing surveillance (PMS) study Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD Year: 2015